AbbVie Reports P-III Study (COMMAND) Results of Skyrizi (risankizumab) for the Treatment of Ulcerative Colitis
- The P-III maintenance study evaluating risankizumab (180/360mg, SC) in 1242 patients. Re-randomized patients from the P-IIb/III study (INSPIRE) who responded to induction therapy received risankizumab (180mg SC, 360mg SC) or withdrew from risankizumab treatment
- The trial met the 1EPs & 2EPs ie., patients received risankizumab 180/360mg @52wk. achieved clinical remission (40% & 38%) vs 25% in the induction-only control group; endoscopic improvement (51% & 48% vs 32%); histologic endoscopic mucosal improvement (43% & 42% vs 23%); steroid-free clinical remission (40% & 37% vs 25%), respectively
- The safety profile was consistent with prior studies with no new safety risks, SAEs (5.2% & 5.1% vs 8.2%), no adjudicated MACE & no adjudicated anaphylactic reaction events were seen
Ref: PRNewswire | Image: AbbVie
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.